KR20090129669A - Manufacturing method of polymeric microspheres - Google Patents

Abstract

PURPOSE: A method for manufacturing polymeric microspheres is provided to obtain polymer spherical particles having uniform size at high yield while not using an organic solvent with body toxicity and to control the size of the polymer spherical particle. CONSTITUTION: A method for manufacturing polymeric microspheres comprises the steps of: mixing uneven polymer particles and sol-phase polymer matrix aqueous solution in a weight ratio of 1 : 10~100 to disperse polymer particles within the sol-phase polymer matrix; gelling a sol-phase polymer matrix in which the polymer is dispersed; melting the polymer particles dispersed inside the gelled polymer matrix to make uneven spherical polymer particles; liquedifying the gelled polymer matrix; and separating and drying the polymer spherical particles from the matrix separator.

Description

Manufacturing method of polymeric microspheres

The present invention uniformly mixes and disperses polymer particles of non-uniform form in a polymer matrix (solution) that becomes a sol-gel phase transition, and gels the sol-like polymer matrix to stably position the dispersed polymer particles in the gel matrix. After heating to a temperature above the melting point of the polymer particles, the non-uniform polymer particles form thermodynamically stable spherical particles without melting and contact with neighboring particles in the gel-like matrix, followed by cooling and removal of the solution-like polymer matrix. As a spherical particle produced through, it is very simple to manufacture compared to other conventional spherical particles, it is possible to obtain a spherical particle of the desired size in a very high yield, it is possible to manufacture without using an organic solvent spherical particles and a manufacturing method thereof To provide.

Tissue engineering, as established at the first tissue engineering symposium in California in 1988, integrates the basic concepts and techniques of bioscience and engineering to understand and correlate the structure and function of biological tissues. It is an applied science that aims to maintain, improve or restore the function of our bodies by making and transplanting substitutes for tissues. Important factors in tissue engineering are, above all, the selection of appropriate cells for cultivating necessary tissues, biodegradable materials that provide a framework for tissue formation, and the environment in which the organs manufactured by tissue engineering techniques will be implanted. The cells to be used in tissue engineering must be healthy, not only perform well the cell's own functions, but also have the following elements: Three-dimensional tissue formation should be possible by interacting with the secretory function of extracellular matrix and interacting with other cells or biomaterials. In addition, it is important to secure a sufficient amount to cultivate the cells in vitro, and careful selection of autologous or heterologous cells in consideration of immunological rejection is important.

Next, an important element in tissue engineering is biodegradable materials that provide a framework for tissue formation. In 1960, it was difficult to process biodegradable polymers such as polylactic acid (PLA) and polyglycolic acid (PGA). It has been neglected to change, but it has been actively studied since the biodegradability of materials could play an important role in tissue engineering. In particular, these biodegradable polymers have been approved by the US Food and Drug Administration (FDA) as non-toxic polymers for human use.

The main requirement for biodegradable polymeric materials in tissue engineering is to provide a framework that allows cells to adhere to the surface of the material to form a three-dimensional structure, and that the transplanted cells adhere evenly within the support. The biodegradable polymer material must be able to maintain its shape even after decomposing and disappearing after a certain period of time. In particular, the cells should adhere evenly within the support and grow well without necrosis, which is a very important factor related to the success or failure of tissue engineering.

In addition, an important factor in tissue engineering is the in vivo environment in which artificial organs will be implanted. When cultured cells and polymer materials are transplanted into the body, they are placed in a biochemical and physical environment that is completely different from in vitro. The factors that determine the biochemical environment are the location of the implant, the permeability of the biomaterial, and the material transport capacity. Can be. The environment in which the implant is located plays an important role in the survival and function of the cell and should be carefully considered. Cells can grow well only when there is sufficient supply of surrounding oxygen or nutrients, and the innermost cells in artificial biological tissues are located farthest from these sources, which puts them at risk for growth. Therefore, the permeability of the biomaterial should be properly adjusted or the surrounding environment should be changed according to the permeability of the material.

Porous supports made of biodegradable polymers have played a significant role in the rapid development of tissue engineering to regenerate tissue from desired cells and implant it into the human body to maintain and restore the function and shape of damaged organs. The uniform distribution of cells in the scaffold and the smooth supply of culture medium are recognized as important factors for success and failure in tissue engineering.

In general, biodegradable polymers that are licensed for human use by the FDA, which are used for porous supports, are not only hydrophobic on the porous surface, but also have a disk shape. Therefore, when the cells are cultured there, the culture solution is not smoothly supplied into the polymer support. The necrosis of cells has been observed, and also has the disadvantage that complicated and cumbersome surgery is required for the actual patient. In order to solve this problem, a spherical particle having a size of micro units that can be injected into a shell can be removed from the conventional disc-shaped support (which has the advantage of being able to be transplanted without surgery because the particle size is small). Attention has been focused on the O / W emulsion / evaporation method which mixes the polymer-dissolved solution and the aqueous solution to form an emulsion solution and evaporates the solvent, and emulsifies the aqueous solution in the polymer solution. W / O / W emulsion solvent extraction / evaporation method, which evaporates the solvent by making a solution and emulsifying it in aqueous solution, and precipitation method of precipitating the polymer solution in the non-solvent. method), a spray drying method in which a polymer is dissolved in an organic solvent, sprayed through a nozzle, and rapidly dried using hot air (spray d). rying method), a study on the preparation of spherical particles using a hot melt technique in which the molten polymer is dispersed in a suitable medium and then cooled slowly, and various tissue engineering fields (artificial skin, artificial cartilage, bone) Research into the application of fillers, molded prosthetics, incontinence therapy, etc.) is being actively conducted. Despite this intensive research and necessity, the polymer spherical particles prepared in the prior art are very difficult to completely remove the organic solvents exhibiting human toxicity during the manufacturing process, difficult to control the size of the spherical particles, and furthermore, particles of the desired size. Since it is known that the yield is very low, it is urgent to develop a method for selectively obtaining polymer spherical particles having a desired size and a method for preparing polymer spherical particles having a high yield.

Accordingly, the present inventors have made continuous research and efforts to solve problems such as residual organic solvent, non-uniform particle size of polymer spherical particles, and low yield, which are generated in the production of existing polymer spherical particles, resulting in sol-gel phase transition. By dispersing the polymer particles having a non-uniform shape and size in the polymer matrix in the sol state using a matrix, and then the phase transition of the polymer matrix in the sol state to the gel state is stabilized and uniform distribution of the inside of the matrix It is possible, and by applying heat above the melting point of the dispersed polymer particles, it can be obtained through the experiment that the spherical particles having a uniform size distribution can be completed through the present invention.

The present invention for solving the above problems relates to a method for producing a polymer spherical particles having a uniform size, by mixing a non-uniform polymer particles and a sol-like polymer matrix aqueous solution in a weight ratio of 1: 10 to 100 sol-like polymer Dispersing the polymer particles in the mattress; A second step of gelling the sol-like polymer matrix having the polymer particles dispersed therein; A third step of melting the polymer particles dispersed in the gelled polymer matrix to spheroidize the polymer particles having an irregular shape; And a fourth step of resolving (solution) of the gelled polymer matrix having the spherical polymer particles dispersed therein; And a fifth step of separating and drying the polymer spherical particles from the resolvated polymer matrix.

In addition, an object of the present invention is to provide a polymer spherical particles having a uniform size produced by the manufacturing method.

Unlike the manufacturing method of the polymer spherical particles, the above-mentioned manufacturing method has the advantage that there is no use of organic solvents with human toxicity, and it is possible to control the size of the polymer spherical particles to be obtained, and in particular, very high yield. As an advantage, it is possible to obtain polymer spherical particles having a uniform size. Furthermore, the polymer spherical particles prepared by the production method of the present invention having such an advantage can be widely applied to various fields such as the chemical field and the semiconductor field using the polymer, in particular, artificial skin, artificial cartilage, bone filler, molded prosthesis. The application is possible in the field of tissue engineering to manufacture a back.

The present invention will be described in detail below.

Method for producing the polymer spherical particles of the present invention

A first step of dispersing the polymer particles in the sol-type polymer mattress by mixing the polymer particles in the uniform form and the aqueous solution of the polymer matrix in the sol phase in a weight ratio of 1:10 to 100;

A second step of gelling the sol-like polymer matrix having the polymer particles dispersed therein;

A third step of melting the polymer particles dispersed in the gelled polymer matrix to spheroidize the polymer particles having an irregular shape; And

A fourth step of resolving (solution) of the gelled polymer matrix having the spherical polymer particles dispersed therein; And

And a fifth step of separating and drying the polymer spherical particles from the resolvated polymer matrix.

Hereinafter, the matrix containing the polymer particles is referred to as "polymer particle-matrix".

When explaining the present invention in more detail,

The polymer particles are pulverized polymer particles in a non-uniform form, and the polymer particles may be used by selecting conductive or non-conductive polymer particles, metallic or non-metallic polymer particles, biodegradable polymer particles, etc. according to their application fields.

In particular, when using the present invention in the field of tissue engineering, a biodegradable polymer is used. In this case, the biodegradable polymer is intended for human use and should have biocompatibility. The biodegradable polymer that can be used in the present invention is not particularly limited, but the biodegradable polymer may have an average molecular weight of 1,000 to 1,000,000 g / mol, preferably 1,000 to 500,000 g / mol, which is the average molecular weight. If this is less than 1,000 g / mol may cause a problem of too weak physical properties, if it exceeds 1,000,000 g / mol because the viscosity is too high at the time of melting may cause a problem that the ability to form spherical particles falls.

The biodegradable polymer is a homopolymer or a polymer polymerized with a single polymer polymerized with one or more selected from lactic acid, glycolic acid, caprolactone, dioxanone, hydroxybutyric acid, hydroxyvaleric acid, phosphoester, and ethylene oxide. Coalescing may be used, more preferably polylactic acid (poly (lactic acid)), polyglycolic acid (poly (glycolic acid)), polycaprolactone (poly-ε-caprolactone), polydioxanone (polydioxanone), Polyhydroxy-valeric acid, polylactic acid-co-glycolic acid (poly), polydioxanone-ca-lacrolactone (polydioxanone-co-ε-caprolactone) ), Polylactic acid-caprolactone copolymer (poly (lactic acid-co-ε-caprolactone)), polyhydroxybutyric acid-hydroxybalic acid copolymer (polyhydroxybutyric acid-co-hydroxyvaleric acid), polyphosphoester (poly (phosphoester)) , A polyethylene oxide-polylactic acid copolymer, a polyethylene oxide-polylactic glycolic acid copolymer, or a polyethylene oxide-polycaprolactone copolymer may be selected and used.

The irregularly shaped polymer particles may be formed of conductive or non-conductive polymer particles, metallic or non-metallic polymer particles, biodegradable polymer particles, etc. using a mill or freezer mill generally used in the art. It is prepared by pulverizing, in this case, it is preferable that the polymer particles have an average diameter of 0.1 μm to 3,000 μm, more preferably 1 μm to 2,000 μm. Herein, when the polymer particles are less than 0.1 μm, the particle size may be so small that it may be difficult to select irregular polymer particles. When the polymer particles are more than 3,000 μm, the particle size is too large, which is uneconomical to produce spherical particles by the manufacturing method of the present invention. It is preferable to use polymer particles having a diameter within the above range because

The polymer matrix used in the present invention is a polymer matrix which is a sol-gel phase transition. In the first step, the mixing ratio of the polymer particles and the sol-like polymer matrix aqueous solution is 1:10 to 100 weight ratio, more preferably 1: It is preferable to have a weight ratio of 30 to 70, wherein if the weight ratio is less than 1: 10 weight ratio, there is a problem that the particles are in contact with each other in the melting process of the polymer to prevent the formation of particles of uniform size, and if the weight ratio exceeds 100 weight ratio, the phase transition Unnecessarily wasting polymer matrix.

Hereinafter, the polymer matrix having the sol-gel phase transition used in the present invention will be described in detail.

[Polymer Matrix with Sol-Gel Phase Transition]

In the present invention, the reason for using a polymer matrix having a sol-gel phase transition rather than a general polymer matrix is to stabilize the polymer particles having the irregular shape and size, that is, when the irregular polymer particles are dispersed in the general polymer matrix, When the polymer particles sink or become unevenly distributed in the polymer matrix, and heat is applied to the polymer particles in this state, spherical particles are not only very hard to make spherical particles due to contact between neighboring polymer particles in the aqueous matrix solution. The yield is also very low. Therefore, the present invention mixes the polymer particles in the aqueous solution of the polymer matrix in the sol state, and then phase-transfers them to a gel state, so that the uniformly distributed polymer particles can be maintained in the distribution, and thus the polymer particles are initially positioned. By maintaining heat at a melting point of the polymer particles in a maintained state to produce spherical particles, the yield of spherical particles can be increased by preventing and blocking contact between neighboring polymer particles in the matrix.

The polymer matrix of the sol phase polymer matrix aqueous solution of the first step is a polymer having an average molecular weight of 1,000 g / mol ~ 1,000,000 g / mol, polyethylene oxide-polypropylene oxide copolymer (Pluronic series), polyethylene oxide-polylactic acid air It is possible to use one or two or more selected from among copolymers, polyethylene oxide-polylactic glycolic acid copolymers, polyethylene oxide-polycaprolactone copolymers, alginic acid, hyaluronic acid, carboxymethylcellulose and dextran.

The polymer matrix having a sol-gel phase transition used in the present invention may be a phase transition from a sol to a gel phase by a temperature or by a crosslinking agent. First, the polymer matrix having a sol-gel phase transition by temperature will be described in detail. would.

Polymer Matrix with Sol-gel Phase Transition by Temperature

The polymer matrix that becomes the sol-gel phase transition by temperature means that the sol-gel phase transition temperature is changed according to the type of the polymer matrix, and the sol-gel phase transition temperature can be controlled according to the concentration of the polymer matrix and its composition ratio. The specific example will be described below.

When using a polymer matrix that is subjected to sol-gel phase transition by temperature, it is preferable to use a polymer matrix having an average molecular weight of 1,000 to 500,000 g / mol, and a polyethylene oxide-polypropylene oxide (PEO-PPO) copolymer and a polyethylene oxide-poly It is preferable to use a polymer matrix including one or two or more copolymers selected from lactic acid copolymers, polyethylene oxide-polylactic glycolic acid copolymers, and polyethylene oxide-polycaprolactone copolymers.

The polyethylene oxide-polypropylene oxide copolymer may use a Pluronic series (BAS, USA), specifically Pluronic F-38, Pluronic F-68, Pluronic F-77 Or a combination of two or more species selected from Pluronic F-87, Pluronic F-88, Pluronic F-98, Pluronic F-108, and Pluronic F-127 can be used.

The polymer matrix which becomes the sol-gel phase transition by temperature is characterized by being a sol phase below the sol-gel phase transition temperature, a gel phase above the sol-gel phase transition temperature, and a sol phase again above a certain temperature.

The sol-gel phase transition temperature can be adjusted according to the concentration of the polymer matrix and its composition ratio. For example, when using a polyethylene oxide-polypropylene oxide (PEO-PPO) copolymer polymer matrix composed of Pluronic F-127 and Pluronic F-68, the concentration of the PEO-PPO copolymer may increase. When the gel phase transition temperature is lowered and the PEO-PPO copolymer is at the same concentration, the weight ratio of Pluronic F-127 increases with respect to the weight ratio of Pluronic F-127 and Pluronic F-68. It can be seen from FIG. 4 that the sol-gel phase transition temperature increases as the gel phase transition temperature decreases and the weight ratio of Pluronic F-68 increases [Oh et al., J. Biomed. Mater. Res ., 72A, 306 (2005)].

When using an aqueous polymer matrix solution that becomes a sol-gel phase transition by temperature, it is preferable to use one containing 1 to 50% by weight, more preferably 10 to 30% by weight, based on the total weight of the aqueous solution. Here, if the polymer matrix is less than 1% by weight, there is a problem in that sol-gel phase transition does not appear, and when the content is greater than 50% by weight, a high viscosity of the sample causes difficulty in uniform mixing with the pulverized particles. It is preferable to use a polymer matrix aqueous solution containing a matrix.

Polymer matrix with sol-gel phase transition by crosslinking

The aqueous solution of the polymer matrix of the sol phase of the first step may include a crosslinking agent. In this case, the polymer matrix of the aqueous solution may have an average molecular weight of 10,000 g / mol to 1,000,000 g / mol, more preferably 30,000 g / mol to 800,000. One having g / mol can be used. When the sol-like polymer matrix aqueous solution includes a crosslinking agent, it is preferable to use a polymer matrix including one or a mixture of two or more selected from alginic acid, hyaluronic acid, carboxymethylcellulose and dextran.

Here, the crosslinking agent may be selected from Mg ²⁺ , Ca ²⁺ , Sr ²⁺ , Ba ^2+, one or two or more kinds of cations; or

A crosslinking agent including chitosan, glutaraldehyde, formalin and poly-L-lysine, one or two or more selected from them can be used.

In the present invention, in the case of using an aqueous polymer matrix having a sol-gel phase transition by crosslinking, 0.1 wt% to 10 wt% of the polymer matrix having a sol-gel phase transition by crosslinking is more preferably based on the total weight of the aqueous solution. It is preferable to use an aqueous solution containing 0.4 wt% to 4 wt%. Here, if less than 0.1% by weight, there is a problem that the physical properties of the cross-linked matrix is too weak to separate the pulverized particles into their respective spaces, and when more than 10% by weight, the uniform viscosity of the sample is high due to the high viscosity of the sample. There is a difficult problem.

In the first step, when using a polymer matrix having a sol-gel phase transition by crosslinking the polymer matrix of the aqueous solution of the sol-like polymer matrix, 0.01 wt% to 20 wt% of the crosslinking agent based on the total weight of the aqueous solution More preferably, those containing 0.3 wt% to 5 wt% are used. At this time, when the content of the crosslinking agent is less than 0.01% by weight, there is a problem in that crosslinking cannot be formed, and when the amount of the crosslinking agent is more than 20% by weight, there is a problem of waste of the crosslinking agent due to the use of more than necessary crosslinking agent.

In the second step, as described above, in order to phase change the polymer particle-matrix aqueous solution from the sol phase to the gel phase, the temperature is increased to the sol-gel phase transition temperature, or the aqueous solution is 0.1 wt% to 10% based on the total weight of the aqueous solution. What is necessary is just to add so that it may contain weight%.

In the third step, in order to melt the polymer particles, heat may be applied above the melting point of the polymer particles, which temperature is 5 ° C. to 50 ° C., more preferably 5 ° C. to 15 ° C. above the melting point of the polymer particles used. It is good to keep warm. Herein, the polymer particles may be incompletely melted when heated to less than 5 ° C., and if too high heat is applied above 50 ° C., the polymer may be pyrolyzed and the gel polymer matrix may become a sol-based matrix. It is good to heat the heat within the range. In the third step, the polymer matrix, which is already phase-transformed from sol to gel, does not change into sol again in the temperature range for melting the polymer particles even when heated to a temperature above the melting point of the polymer particles.

In the fourth step, the polymer matrix is converted into an aqueous solution of the gel-like polymer particle-matrix into an sol-like polymer particle-matrix solution by cooling (when using a phase-transfer matrix with temperature) or crosslinking dissolving agent (when using a phase-transfer matrix with crosslinking). Let's do it.

In this case, the crosslinking dissolving agent may be used by mixing one or more selected from sodium citrate, sodium chloride, sodium bicarbonate, sodium phosphate and sodium hydroxide.

In the fifth step, the polymer spherical particles can be prepared by washing the polymer matrix subjected to resolving (solution) to separate the polymer spherical particles, and drying the separated polymer spherical particles. At this time, the washing, separation and drying may be used in the general method used in the art, it is not particularly limited.

Through the first step to the fifth step as described above is to obtain a polymer spherical particles having a uniform size with a high yield.

The polymer spherical particles of the present invention has the advantage of not using any organic solvent showing human toxicity in the manufacturing method, and because it has a uniform particle size can be easily introduced into the application site through injection injection, tissue It can be very usefully used as an engineering support and various fillers (molding implants, bulking agents for treating incontinence, etc.). In addition, the application is also possible in the chemical field, electrical, electronic field, etc. that require fine-sized polymer spherical particles.

Although this invention is demonstrated in detail based on an Example, this invention is not limited to an Example.

Example 1

Polycaprolactone (PCL, melting point: 60 ℃), which is a polymer, is pulverized into micro particles using a freezer mill (SPEX 6750, CentiPrep Inc., USA), and then micro sieves are used for micro particle separation. To obtain a polymer particle having a heterogeneous form separated as follows by size. 50 µm <d <100 µm, 100 µm <d <200 µm, 200 µm <d <300 µm, 300 µm <d <425 µm, 425 µm <d <500 µm, where d is the average diameter of the polymer particles. Mix the polymer particles in a 1:50 weight ratio (4 ° C.) and polymer particles in a sol-like polymer matrix aqueous solution containing 17.5% by weight of each of the four types of polymer particles separated into four distribution sizes and Pluronic F127 as described above. Four sol-like aqueous polymer matrix solutions in which polymer particles were dispersed were dispersed by dispersing in a matrix Pluronic F127. The sol-like polymer matrix aqueous solution was allowed to stand at room temperature (25 ° C.) for 1 hour to induce a gel phase. At this time, the sol-gel phase transition temperature (LCST, lower critical solution temperature) is approximately 25 ℃ (Fig. 4), each of the polymer particles are independently dispersed in the gel polymer aqueous solution is uniformly distributed. Thus prepared polymer matrix aqueous solution in which the polymer particles were dispersed was placed for 30 minutes in a thermostat preheated to 65 ° C., at a temperature above the melting point of PCL. Then, while storing the gel matrix aqueous solution at 65 ° C., the PCL particles, which are polymer particles, are changed into a thermodynamically stable sphere without melting and contact with surrounding particles at the same time inside the gel polymer matrix. After the melting and spheronization process, the gel polymer matrix aqueous solution was cooled at room temperature for 1 hour, and the gel polymer matrix was resolvated at 4 ° C. Washing with water at 4 ° C. for 24 hours completely removed the polymeric matrix Floronic F127 matrix. After removal, the remaining PCL spherical particles were dried in a vacuum oven at room temperature for one day to obtain PCL spherical particles having a uniform particle size.

Example 2

Polycaprolactone (PCL, melting point: 60 ℃), which is a polymer, is pulverized into micro particles using a freezer mill (SPEX 6750, CentiPrep Inc., USA), and then micro sieves are used for micro particle separation. To obtain a polymer particle having a heterogeneous form separated as follows by size. 50 µm <d <100 µm, 100 µm <d <200 µm, 200 µm <d <300 µm, 300 µm <d <425 µm, 425 µm <d <500 µm, where d is the average diameter of the polymer particles.

Each of the polymer particles separated into a constant size, 1% by weight of alginic acid and 0.4% by weight of CaSO ₄ was mixed in a 1:50 weight ratio (at room temperature), and a sol-like polymer matrix solution in which the polymer particles were dispersed. 4 made. The aqueous solution of the polymer matrix on the sol was left at room temperature for about 2 hours to induce alginic acid into the gel. The gelled polymer matrix was placed in a thermostat preheated to 65 ° C., above the melting point of the PCL, for 30 minutes. After melting and spheronizing the PCL particles of the aqueous solution of the polymeric polymer-matrix on the gel, the aqueous solution is cooled at room temperature for 1 hour, the gel phase is resolvated in 2% aqueous sodium citrate solution for 24 hours, It was washed with water. The prepared PCL spherical particles were dried in a vacuum oven at room temperature for one day to obtain PCL spherical particles.

Examples 3-4

Examples 3 to 4 were carried out in the same manner as in Example 1, but as polymer particles, Example 3 prepared spherical particles by using a thermostat preheated to 60 ° C of polyhydroxybalaric acid (melting point 53 ° C). , Example 4 prepared spherical particles using a thermostat preheated to 55 ℃ polyvinyl butyral (melting point 49 ℃), not a biodegradable polymer.

Examples 5-6

Examples 5 to 6 were carried out in the same manner as in Example 2, but as polymer particles, Example 6 prepared spherical particles by using a thermostat preheated to 60 ℃ polyhydroxy valeric acid (melting point 53 ℃) In Example 6, spherical particles were prepared using a thermostat preheated to 55 ° C. instead of biodegradable polymer polyvinyl butyral (melting point 49 ° C.).

Example 7

In the same manner as in Example 1, a polymer matrix having a sol-gel phase transition was used in which Floronic F127 and Floronic F68 had a weight ratio of 7: 3, containing 33 wt% of the polymer matrix having the weight ratio. The same polymer particles as in Example 1 were mixed with the aqueous gel-like polymer matrix solution, and the sol-like polymer matrix was changed into a gel at approximately 25 ° C.

Comparative Example 1

The same polycaprolactone (PCL) as in Example 1 was used, but spherical particles were prepared using a conventional phase separation method [Oh et al., Biomaterials , 27, 1936 (2006)]. PCL and surfactant Tween 80 and Pluronic F127 matrix were mixed at a constant ratio (PCL: Pluronic F127: Tween 80 = 1: 4: 5 weight ratio), heated, stirred, cooled, and washed to 130 ° C. for fine particle separation. (Micro sieve) was used to separate by size to obtain a polymer spherical particles.

Experimental Examples 1-1 to 7-4 and Comparative Experimental Examples 1-1 to 1-4

Size Distribution Experiment of Polymer Spherical Particles

The pulverized particles and the prepared spherical particles of the examples and comparative examples were observed through an electron scanning electron microscope (SEM), the results are shown in Figures 2 and 3, the particle size and distribution of these are shown in Table 1 below. Indicated. At this time, the shape and diameter of the pulverized polymer particles and spherical particles were measured using an electron scanning microscope measurement and image analysis program of the measured picture.

Experimental Example for the Example of the Present Invention When the spherical particles were prepared by the method of the present invention using the irregularly shaped polymer particles of the size to be obtained through Table 1, to obtain a high yield of 90% or more It can be seen that spherical particles of size can be prepared. However, in the case of Comparative Example 1, which is a spherical particle prepared by the existing manufacturing method, it can be confirmed that the yield is very low as 20% or less.

Preparation Example and Experimental Example 8

Sol-Gel Phase Transition Temperature Identification Experiment

In order to confirm the phase transition temperature of the polymer matrix having the sol-gel phase transition by the temperature, 20% by weight of the polymer matrix having the Pluronic F-127 and Pluronic F-68 having a weight ratio of 10:10 to 0:10, A sol-gel phase transition polymer matrix containing 25 wt%, 30 wt%, 35 wt%, 40 wt% and 45 wt% was prepared, and an experiment was performed to confirm the phase transition temperature, and the results are shown in FIG. 4.

The polymer spherical particle manufacturing method of the present invention has the advantage of not using any organic solvent exhibiting human toxicity, unlike the existing polymer spherical particle manufacturing method, it is possible to manufacture the polymer spherical particles of the desired size with a high yield. . The polymer spherical particles prepared by the manufacturing method of the present invention can be widely applied not only in the chemical field, the electric field, the electronic field, etc., but also in the field of tissue engineering for manufacturing artificial skin, artificial cartilage, bone filler, molded prosthesis, and the like. .

Figure 1 is a representative schematic diagram of the present invention to form a spherical particles of uniform shape from the irregularly shaped polymer particles.

2 is an electron micrograph of the polymer particles used in Example 1 and the spherical particles prepared in Example 1, (A) shows the polymer particles having a non-uniform shape, (B) is an electron microscope of the prepared spherical particles It is a photograph.

Figure 3 is a scanning electron microscope (SEM) photograph showing the spherical particles prepared by Experimental Example 1-1 to Experimental Example 1-4, the results showing that the size of the spherical particles is adjusted according to the size of the polymer particles.

Figure 4 is a graph showing the sol-gel phase transition temperature change according to the concentration of the polymer matrix tested in Experimental Example 10 and its polymer composition ratio.

Claims (11)

A first step of dispersing the polymer particles in the sol-like polymer mattress by mixing the non-uniform polymer particles and the sol-like polymer matrix aqueous solution in a weight ratio of 1:10 to 100; A second step of gelling the sol-like polymer matrix having the polymer particles dispersed therein; A third step of melting the polymer particles dispersed in the gelled polymer matrix to spheroidize the polymer particles having an irregular shape; And A fourth step of resolving (solution) of the gelled polymer matrix having the spherical polymer particles dispersed therein; And And a fifth step of separating and drying the polymer spherical particles from the resolvated polymer matrix. According to claim 1, wherein the polymer particles are conductive or non-conductive polymer; Metallic or nonmetallic polymers; Or a biodegradable polymer; method for producing the polymer spherical particles, characterized in that. According to claim 2, wherein the biodegradable polymer has an average molecular weight of 1,000 g / mol to 1,000,000 g / mol, lactic acid, glycolic acid, caprolactone, dioxanone, hydroxybutyric acid, hydroxyvalic acid, phosphoester And a homopolymer polymerized with a single species selected from ethylene oxide or a copolymer polymerized with two or more species. The method according to claim 1, wherein the irregularly shaped polymer particles have a mean diameter of 0.1 μm to 3,000 μm. The method according to claim 1, wherein the polymer matrix has a mean molecular weight of 1,000 g / mol to 1,000,000 g / mol and is a polymer matrix which is a sol-gel phase change by temperature or crosslinking. According to claim 5, wherein the polymer matrix to be the sol-gel phase change by the temperature is a polymer matrix having an average molecular weight of 1,000 to 500,000 g / mol, polyethylene oxide-polypropylene oxide copolymer, polyethylene oxide-polylactic acid copolymer, poly A method for producing a polymer spherical particle, characterized in that the polymer matrix comprising a single or two or more selected from ethylene oxide-polylactic glycolic acid copolymer, polyethylene oxide-polycaprolactone copolymer. The method according to claim 1, wherein the aqueous polymer matrix solution of the first step contains 1% by weight to 50% by weight of a polymer matrix which is subjected to sol-gel phase transition by temperature. According to claim 5, wherein the polymer matrix of the aqueous solution of the polymer matrix to be sol-gel phase change by crosslinking has an average molecular weight of 10,000 g / mol ~ 1,000,000 g / mol, the polymer matrix is alginic acid, hyaluronic acid, carboxymethyl cellulose And dextran selected from the group consisting of single or two or more polymer matrix. The method according to claim 1, wherein the aqueous solution of the polymer matrix to be the sol-gel phase transition by crosslinking contains 0.1 to 10% by weight of the polymer matrix to be the sol-gel phase transition by crosslinking and 0.01 to 20% by weight of the crosslinking agent. Method for producing a polymer spherical particles, characterized in that. The method of claim 9, wherein the crosslinking agent Single or two or more cations selected from Mg ²⁺ , Ca ²⁺ , Sr ²⁺ , Ba ²⁺ ; or Preparation of polymeric spherical particles comprising chitosan, glutaraldehyde, formalin and poly-L-lysine Way. The method according to claim 1, wherein the melting temperature of the polymer particles is maintained at 5 ° C to 20 ° C higher than the melting point of the polymer particles.

Images